146 related articles for article (PubMed ID: 25159161)
1. CXCR2 receptor antagonists: a medicinal chemistry perspective.
Dwyer MP; Yu Y
Curr Top Med Chem; 2014; 14(13):1590-605. PubMed ID: 25159161
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 3,4-diaminocyclobut-3-ene-1,2-dione-based CXCR2 receptor antagonists for the treatment of inflammatory disorders.
Dwyer MP; Biju P
Curr Top Med Chem; 2010; 10(13):1339-50. PubMed ID: 20536426
[TBL] [Abstract][Full Text] [Related]
3. CCR1 and CCR2 antagonists.
Zimmermann HW; Sterzer V; Sahin H
Curr Top Med Chem; 2014; 14(13):1539-52. PubMed ID: 25159163
[TBL] [Abstract][Full Text] [Related]
4. The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists.
Porter DW; Bradley M; Brown Z; Canova R; Charlton S; Cox B; Hunt P; Kolarik D; Lewis S; O'Connor D; Reilly J; Spanka C; Tedaldi L; Watson SJ; Wermuth R; Press NJ
Bioorg Med Chem Lett; 2014 Jan; 24(1):72-6. PubMed ID: 24332493
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptor.
de Kruijf P; van Heteren J; Lim HD; Conti PG; van der Lee MM; Bosch L; Ho KK; Auld D; Ohlmeyer M; Smit MJ; Wijkmans JC; Zaman GJ; Smit MJ; Leurs R
J Pharmacol Exp Ther; 2009 May; 329(2):783-90. PubMed ID: 19190236
[TBL] [Abstract][Full Text] [Related]
6. CXCR2 modulators: a patent review (2009 - 2013).
Dwyer MP; Yu Y
Expert Opin Ther Pat; 2014 May; 24(5):519-34. PubMed ID: 24555661
[TBL] [Abstract][Full Text] [Related]
7. Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers.
Xie Y; Kuang W; Wang D; Yuan K; Yang P
Eur J Med Chem; 2023 Mar; 250():115175. PubMed ID: 36780833
[TBL] [Abstract][Full Text] [Related]
8. CXCR2 antagonists for the treatment of pulmonary disease.
Chapman RW; Phillips JE; Hipkin RW; Curran AK; Lundell D; Fine JS
Pharmacol Ther; 2009 Jan; 121(1):55-68. PubMed ID: 19026683
[TBL] [Abstract][Full Text] [Related]
9. Medicinal chemistry of small molecule CCR5 antagonists for blocking HIV-1 entry: a review of structural evolution.
Tian Y; Zhang D; Zhan P; Liu X
Curr Top Med Chem; 2014; 14(13):1515-38. PubMed ID: 25159164
[TBL] [Abstract][Full Text] [Related]
10. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases.
Busch-Petersen J
Curr Top Med Chem; 2006; 6(13):1345-52. PubMed ID: 16918453
[TBL] [Abstract][Full Text] [Related]
11. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
12. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist.
Nicholson GC; Tennant RC; Carpenter DC; Sarau HM; Kon OM; Barnes PJ; Salmon M; Vessey RS; Tal-Singer R; Hansel TT
Pulm Pharmacol Ther; 2007; 20(1):52-9. PubMed ID: 16406722
[TBL] [Abstract][Full Text] [Related]
13. Chemokine receptors in airway disease: which receptors to target?
Owen C
Pulm Pharmacol Ther; 2001; 14(3):193-202. PubMed ID: 11448146
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel small molecule CCR2 antagonists: evaluation of 4-aminopiperidine derivatives.
Vilums M; Zweemer AJ; Dekkers S; Askar Y; de Vries H; Saunders J; Stamos D; Brussee J; Heitman LH; IJzerman AP
Bioorg Med Chem Lett; 2014 Dec; 24(23):5377-80. PubMed ID: 25453791
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis.
Min SH; Wang Y; Gonsiorek W; Anilkumar G; Kozlowski J; Lundell D; Fine JS; Grant EP
Biochem Biophys Res Commun; 2010 Jan; 391(1):1080-6. PubMed ID: 20004647
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models.
Ha H; Debnath B; Odde S; Bensman T; Ho H; Beringer PM; Neamati N
J Chem Inf Model; 2015 Aug; 55(8):1720-38. PubMed ID: 26153616
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
Nicholls DJ; Wiley K; Dainty I; MacIntosh F; Phillips C; Gaw A; Mårdh CK
J Pharmacol Exp Ther; 2015 May; 353(2):340-50. PubMed ID: 25736418
[TBL] [Abstract][Full Text] [Related]
18. Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.
Cherney RJ; Brogan JB; Mo R; Lo YC; Yang G; Miller PB; Scherle PA; Molino BF; Carter PH; Decicco CP
Bioorg Med Chem Lett; 2009 Feb; 19(3):597-601. PubMed ID: 19131247
[TBL] [Abstract][Full Text] [Related]
19. The discovery of novel cyclohexylamide CCR2 antagonists.
Lanter JC; Markotan TP; Zhang X; Subasinghe N; Kang FA; Hou C; Singer M; Opas E; McKenney S; Crysler C; Johnson D; Molloy CJ; Sui Z
Bioorg Med Chem Lett; 2011 Dec; 21(24):7496-501. PubMed ID: 22061641
[TBL] [Abstract][Full Text] [Related]
20. Multiple binding sites for small-molecule antagonists at the CC chemokine receptor 2.
Zweemer AJ; Nederpelt I; Vrieling H; Hafith S; Doornbos ML; de Vries H; Abt J; Gross R; Stamos D; Saunders J; Smit MJ; Ijzerman AP; Heitman LH
Mol Pharmacol; 2013 Oct; 84(4):551-61. PubMed ID: 23877010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
